Skip to content

Lucid Diagnostics LUCD Accrued expenses and other liabilities

Accrued expenses and other liabilities at other companies

Fulgent Genetics, Inc. logo
Fulgent Genetics, Inc.FLGT
Personalis, Inc. logo
Personalis, Inc.PSNL
Labcorp Holdings logo
Labcorp HoldingsLH
GRAIL, Inc. logo
GRAIL, Inc.GRAL
Opko Health logo
Opko HealthOPK

Other financials

Income statement

See full
Revenue$1.3M+51.7%
Gross profit-$369.0K+49.0%
Operating income-$12.1M+3.0%
Net income-$13.9M+48.3%
EPS (diluted)-$0.10+60.0%

Balance sheet

See full
Cash & equivalents$27.9M+10.6%
Total debt$1.6M-35.1%
Total equity$4.0M+174%
Total assets$34.1M+3.9%

Cash flow

See full
Operating cash flow-$12.1M+2.9%
CapEx$215.0K+131%
Free cash flow-$12.3M+1.9%

Valuation

See full
Market cap$204.13M+58.5%
Enterprise value$177.85M+78.0%
P/S39.8×+10.2×

Profitability

See full
Gross margin-66.8%
Operating margin-959.6%-133pp
Net margin-876.7%-254pp
FCF margin-1,099.6%

Returns & leverage

See full
Return on equity-710.6%
Debt / equity0.4×
Current ratio1.1×+0.3×

Where this comes from

Reported directly by Lucid Diagnostics in its filing.

Tagged under the XBRL concept us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities.

The official record: Lucid Diagnostics’s 10-Q, filed May 13, 2026, on SEC EDGAR. View the filing →

Ask your AI about Lucid Diagnostics's accrued expenses and other liabilities.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Lucid Diagnostics's accrued expenses and other liabilities?
Lucid Diagnostics (LUCD) reported accrued expenses and other liabilities of -$519K in Q1 2026.
How has Lucid Diagnostics's accrued expenses and other liabilities changed year-over-year?
Lucid Diagnostics's accrued expenses and other liabilities increased by 31.3% year-over-year, from -$756K to -$519K.